Home » Stocks » SBBP

Strongbridge Biopharma PLC (SBBP)

Stock Price: $2.48 USD -0.09 (-3.50%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 174.17M
Revenue (ttm) 32.44M
Net Income (ttm) -44.19M
Shares Out 67.38M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $2.48
Previous Close $2.57
Change ($) -0.09
Change (%) -3.50%
Day's Open 2.58
Day's Range 2.46 - 2.59
Day's Volume 385,778
52-Week Range 1.87 - 4.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the develo...

21 hours ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

22 hours ago - GlobeNewsWire

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

DUBLIN, Ireland and TREVOSE, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...

3 days ago - GlobeNewsWire

~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~

2 weeks ago - GlobeNewsWire

NEW YORK, June 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: First Bancorp (NASDAQ: FBNC)  concerning potential vio...

Other stocks mentioned: AVCO, CLDR, FBNC, XEC
1 month ago - PRNewsWire

DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

1 month ago - GlobeNewsWire

NEW YORK, May 29, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action ...

2 months ago - PRNewsWire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge Bioph...

Other stocks mentioned: XERS
2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc (NASDAQ: SBBP) to Xeris Pharmaceuticals, Inc. is fair to S...

2 months ago - Business Wire

NEW YORK, May 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge Biopharma plc ("Strongbridg...

Other stocks mentioned: XERS
2 months ago - PRNewsWire

CHICAGO and DUBLIN and TREVOSE, Pa., May 24, 2021 /PRNewswire/ -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop an...

Other stocks mentioned: XERS
2 months ago - PRNewsWire

Penny stocks are in focus as we enter the last week of May. Which companies are you watching?

Other stocks mentioned: CREX, CTRM
2 months ago - PennyStocks

Xeris Pharmaceuticals Inc (NASDAQ: XERS) has agreed to acquire Strongbridge Biopharma plc (NASDAQ: SBBP) for stock and contingent value rights (CVRs), valuing Strongbridge at approximately $267 million....

Other stocks mentioned: XERS
2 months ago - Benzinga

CHICAGO & DUBLIN & TREVOSE, Pa.--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and comm...

Other stocks mentioned: XERS
2 months ago - Business Wire

CHICAGO & DUBLIN & TREVOSE, Pa.--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

Other stocks mentioned: XERS
2 months ago - Business Wire

The FDA has accepted to review Strongbridge Biopharma plc's (NASDAQ: SBBP) marketing application for Recorlev (levoketoconazole) to treat endogenous Cushing's syndrome. Earlier than anticipated, the Com...

2 months ago - Benzinga

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of -10.00% and 2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Strongbridge Biopharma (NASDAQ:SBBP) fell 3.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 42.11% over the past year to ($0.11), whic...

2 months ago - Benzinga

~ Reports KEVEYIS ®  (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~

2 months ago - GlobeNewsWire

On Wednesday, May 12, Strongbridge Biopharma (NASDAQ:SBBP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

2 months ago - Benzinga

DUBLIN, Ireland and TREVOSE, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...

2 months ago - GlobeNewsWire

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing's Syndrome and Comorbid Diabetes Mellitus

3 months ago - GlobeNewsWire

Strongbridge Biopharma plc (NASDAQ: SBBP) has announced detailed results from the previously reported Phase 3 LOGICS study of Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome. ...

4 months ago - Benzinga

~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~

4 months ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: INFI, NBEV, FINV, SVRA
4 months ago - 24/7 Wall Street

DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

4 months ago - GlobeNewsWire

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 15.38% and 1.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Strongbridge Biopharma (NASDAQ:SBBP) moved higher by 0.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 56.00% over the past year ...

4 months ago - Benzinga

~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome to U.S. Food & Drug Administration ~

4 months ago - GlobeNewsWire

Strongbridge Biopharma plc (NASDAQ: SBBP) has submitted a marketing application seeking approval for Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome, to the FDA. Endogenou...

4 months ago - Benzinga

~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~

4 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

5 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

5 months ago - GlobeNewsWire

~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Rev...

6 months ago - GlobeNewsWire

~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing's Syndrome ~ ~ RECORLEV™ (levoketoconazole) Tre...

8 months ago - GlobeNewsWire

The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some potential c...

8 months ago - Seeking Alpha

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...

8 months ago - GlobeNewsWire

Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 11.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Study i...

9 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

9 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comm...

10 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comm...

10 months ago - GlobeNewsWire

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP).

10 months ago - PRNewsWire

After reporting positive Recorlev Phase 3 top line data, SBBP management demonstrated incredible confidence by guiding investors to expect $250MM-$350MM/year in peak Recorlev sales/year.

10 months ago - Seeking Alpha

~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To Vi...

10 months ago - GlobeNewsWire

~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in a...

10 months ago - GlobeNewsWire

Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows. If the data does not look good, SBBP options are very limited.

11 months ago - Seeking Alpha

About SBBP

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somato... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2015
CEO
Matthew Pauls
Employees
72
Stock Exchange
NASDAQ
Ticker Symbol
SBBP
Full Company Profile

Financial Performance

In 2020, SBBP's revenue was $30.73 million, an increase of 41.54% compared to the previous year's $21.71 million. Losses were -$45.08 million, -8.85% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SBBP stock is "Strong Buy." The 12-month stock price forecast is 5.83, which is an increase of 135.08% from the latest price.

Price Target
$5.83
(135.08% upside)
Analyst Consensus: Strong Buy